Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cladribine With Intermediate Cytarabine, G-CSF and VP16 Sequential With Fludarabine and Busulifan as Condoning Regimen for Refractory Acute Leukemia

NCT03882203 is registered in ClinicalTrials.gov with Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT03882203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03882203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cladribine With Intermediate Cytarabine, G-CSF and VP16 Sequential With Fludarabine and Busulifan as Condoning Regimen for Refractory Acute Leukemia
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2018
Completion date
December 30, 2022
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic stem cell transplantation, refractory hematologic cancer